진바이오텍
Financials
Valuation Metrics
진바이오텍's Market Cap is ₩412B. At end of 2025 it was ₩345B. Ranked #1856 of 2,436 in KR market (top 76%), #1144 of 1,649 on KOSDAQ (top 69%), #201 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 86%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 41.24B KRW | KR#1,856/2,436 Sec#201/234 |
| Revenue | 89.44B KRW | KR#1,467/2,436 Sec#93/234 |
| Net Income | 3.59B KRW | KR#1,228/2,436 Sec#86/234 |
| Total Assets | 79.46B KRW | KR#1,912/2,436 Sec#160/234 |
| Net Assets | 55.10B KRW | KR#1,805/2,436 Sec#154/234 |
| Employees | 43 | KR#2,086/2,436 Sec#190/234 |
| Value | ||
| P/E | 11.49x | KR#792/2,436 Sec#45/234 |
| P/B | 0.75x | KR#1,202/2,436 Sec#68/234 |
| P/S | 0.46x | KR#869/2,436 Sec#31/234 |
| EV/EBITDA | 12.39x | KR#742/2,436 Sec#40/234 |
| FCF Yield | 9.35% | KR#651/2,436 Sec#29/234 |
| Profitability | ||
| ROE | 6.51% | KR#844/2,436 Sec#64/234 |
| ROA | 4.52% | KR#710/2,436 Sec#57/234 |
| Op. Margin | 4.40% | KR#998/2,436 Sec#77/234 |
| Revenue Growth | -5.91% | KR#1,737/2,436 Sec#161/234 |
| Earnings Growth | -26.15% | KR#1,083/2,436 Sec#68/234 |
| Financial Health | ||
| Debt Ratio | 144.22% | KR#1,113/2,436 Sec#126/234 |
| Total Debt | 16.28B KRW | KR#1,438/2,436 Sec#123/234 |
| FCF | 3.86B KRW | KR#965/2,436 Sec#69/234 |
| Cash | 8.74B KRW | KR#1,747/2,436 Sec#146/234 |
| Current Ratio | 3.01x | KR#615/2,436 Sec#84/234 |
| Net Debt/EBITDA | 1.92x | KR#883/2,436 Sec#64/234 |
| Dividend | ||
| Div. Yield | 1.02% | KR#1,125/2,436 Sec#66/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | 14.05% | KR#477/2,436 Sec#39/234 |
| 1M Return | 10.62% | KR#264/2,436 Sec#17/234 |
| From 52W High | -20.03% | KR#186/2,436 Sec#9/234 |
| 1Y MDD | -35.14% | KR#351/2,436 Sec#24/234 |
| Trading | ||
| Volume | 13,829 shares | KR#2,015/2,436 Sec#202/234 |
| Foreign Own. | 6.76% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 417 KRW | KR#977/2,436 Sec#69/234 |
| BPS | 6,399 KRW | KR#1,256/2,436 Sec#89/234 |
Company Info
Jin Biotek, established in 2000 and headquartered in Gongju-si, Chungcheongnam-do, was founded to manufacture and sell functional feed additives using beneficial microorganisms, listing on KOSDAQ in 2006. In 2011, it acquired Dawon Chemical Co., Ltd., an animal pharmaceutical company, and supplies natural, eco-friendly feed ingredients and additives based on solid-state fermentation technology. The company focuses on developing technologies and products for environmental improvement, greenhouse gas reduction, and pet food, snacks, and supplements, driven by future technology R&D and ESG management.